RNS Number : 4880H

AstraZeneca PLC

28 July 2023

28 July 2023

Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies

Agreement furthers Alexion's ambition to transform patient outcomes with genomic medicine and provides synergistic opportunities across AstraZeneca

Portfolio includes preclinical gene therapy programmes and enabling technologies with potential across several therapeutic areas

Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). The agreement furthers Alexion and AstraZeneca's commitment to advancing next-generation genomic medicines with the addition of complementary pipeline assets and innovative technologies.

As part of the agreement, the transaction will bring to Alexion a number of novel adeno-associated virus (AAV) capsids. AAV capsids have been shown to be an effective mechanism for delivering therapeutic gene cargos for gene therapy and gene editing.(1) These new resources build on Alexion and AstraZeneca's combined capabilities in genomic medicine, recently strengthened with the acquisition of LogicBio, with the objective to develop new genetic therapies with improved safety and efficacy profiles. Additionally, Alexion will seek to welcome talent from Pfizer associated with the portfolio.

Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease, said: "Today's announcement represents another major step forward in Alexion and AstraZeneca's ambition to be an industry leader in genomic medicine, which has potential to be transformative and even curative for patients with devastating diseases. We look forward to continuing our work to develop enhanced platforms and technologies with broad therapeutic application while integrating best-in-class expertise to accelerate promising therapeutics into the clinic."

There are more than 7,000 known rare diseases, and around 80% of rare diseases are believed to be caused by a genetic mutation.(2,3) Genomic medicines are designed to treat or cure these diseases by addressing the malfunctioning gene. This can be done through addition, alteration or inactivation of the gene to help the body fight the disease. (4)

Financial considerations

Under the agreement, Alexion will purchase and licence the assets of Pfizer's early-stage rare disease gene therapy portfolio for a total consideration of up to $1bn, plus tiered royalties on sales.

Alexion plans to close the transaction in Q3 2023, subject to the satisfaction of closing conditions.



Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.


AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @ AstraZeneca .


For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here .


1. Wang D, et al. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019 May;18(5):358-378.

2. FDA. Rare Diseases at FDA. Available at: https://www.fda.gov/patients/rare-diseases-fda. Accessed July 2023.

   3.   European Commission. Expert Group on Public Health. Rare diseases. Available at: https://health.ec.europa.eu/non-communicable-diseases/expert-group-public-health/rare-diseases_en. Accessed July 2023. 
   4.   FDA. How Gene Therapy Can Cure or Treat Diseases. Available at: https://www.fda.gov/consumers/consumer-updates/how-gene-therapy-can-cure-or-treat-diseases. Accessed July 2023. 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

July 28, 2023 02:05 ET (06:05 GMT)

Grafico Azioni Astrazeneca (LSE:AZN)
Da Nov 2023 a Dic 2023 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Da Dic 2022 a Dic 2023 Clicca qui per i Grafici di Astrazeneca